Leading the way to safer medication
 Crosscheck  Recommender

ATC Group: A02BC Proton pump inhibitors

Anatomical Therapeutic Chemical Classification System

Hierarchical Position

Level
Code
Title
1
A
Alimentary tract and metabolism
2
A02
Drugs for acid related disorders
3
A02B
DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)
4
A02BC
Proton pump inhibitors

Contents

Code
Title
A02BC01
Omeprazole
A02BC02
Pantoprazole
A02BC03
Lansoprazole
A02BC04
Rabeprazole
A02BC05
Esomeprazole
A02BC06
Dexlansoprazole
A02BC07
Dexrabeprazole
A02BC08
Vonoprazan
A02BC53
Lansoprazole, combinations
A02BC54
Rabeprazole, combinations

Active Ingredients

Chemical substance
Description
Dexlansoprazole

Dexlansoprazole belongs to a class of antisecretory compounds, the substituted benzimidazoles, that suppress gastric acid secretion by specific inhibition of the (H+, K+)-ATPase at the secretory surface of the gastric parietal cell.

Esomeprazole

Esomeprazole is the S-isomer of omeprazole and reduces gastric acid secretion through a specific targeted mechanism of action. Esomeprazole is a weak base and is concentrated and converted to the active form in the highly acidic environment of the secretory canaliculi of the parietal cell, where it inhibits the enzyme H+ K+ -ATPase – the acid pump and inhibits both basal and stimulated acid secretion.

Lansoprazole

Lansoprazole is a gastric proton pump inhibitor. It inhibits the final stage of gastric acid formation by inhibiting the activity of H+/K+ ATPase of the parietal cells in the stomach. The inhibition is dose-dependent and reversible, and the effect applies to both basal and stimulated secretion of gastric acid.

Omeprazole

Omeprazole, a racemic mixture of two enantiomers reduces gastric acid secretion through a highly targeted mechanism of action. It is a specific inhibitor of the acid pump in the parietal cell. It is rapidly acting and provides control through reversible inhibition of gastric acid secretion with once daily dosing.

Pantoprazole

Pantoprazole is a substituted benzimidazole which inhibits the secretion of hydrochloric acid in the stomach by specific blockade of the proton pumps of the parietal cells.

Rabeprazole

Rabeprazole belongs to the class of anti-secretory compounds, the substituted benzimidazoles, that do not exhibit anticholinergic or H2 histamine antagonist properties, but suppress gastric acid secretion by the specific inhibition of the H+/K+ -ATPase enzyme (the acid or proton pump).

Vonoprazan

Vonoprazan is a potassium competitive acid blocker (PCAB). It inhibits H+, K+-ATPase in a reversible and potassium-competitive manner. Vonoprazan is a strong base with a high affinity for the acid pump of gastric cells inhibiting gastric acid production.

Monographs

Monograph
Type
Country
ACIPHEX Delayed-release tablet
MPI, US: SPL/PLR
US
ACIPHEX SPRINKLE Delayed-release capsule
MPI, US: SPL/PLR
US
DEXILANT Delayed-release capsules
MPI, US: SPL/PLR
US
LANSOPRAZOLE Gastro-resistant capsules
MPI, EU: SmPC
UK
NEXIUM Gastro-resistant granules
MPI, EU: SmPC
UK
NEXIUM Gastro-resistant tablets
MPI, EU: SmPC
UK
NEXIUM Powder for solution for injection / infusion
MPI, EU: SmPC
UK
OMEPRAZOLE Gastro-resistant capsules
MPI, EU: SmPC
UK
OMEPRAZOLE Powder for solution for infusion
MPI, EU: SmPC
UK
PANTOLOC CONTROL Gastro-resistant tablet
MPI, EU: SmPC
PANTOPRAZOLE 20mg Gastro-resistant tablets
MPI, EU: SmPC
UK
PANTOPRAZOLE 40mg Gastro-resistant tablets
MPI, EU: SmPC
UK
PANTOPRAZOLE Powder for solution for injection
MPI, EU: SmPC
UK
PEDIPPI Powder for oral suspension
MPI, EU: SmPC
IE
PREVACID Delayed-release capsule / Delayed-release tablet
MPI, US: SPL/PLR
US
PRILOSEC Granule for delayed-release oral suspension
MPI, US: SPL/PLR
US
RABEPRAZOLE ACCORD Gastro-resistant tablet
MPI, EU: SmPC
UK
ZOTON FASTAB Oro-dispersible tablet
MPI, EU: SmPC
UK